(NewsDirect)
Emergent HealthCorp. (OTC: EMGE), a curator, developer, and marketer ofproducts in the Regenerative Health Space announced that itssubsidiary Evolutionary Biologics, Inc. (“EvoBio”), a developer,manufacturer and distributor of private label regenerative medicineproducts and branded state-of-the-art biologic products, created in apharmaceutical grade laboratory and manufacturing facility hasexecuted a Product Manufacturing Agreement with a distributor ofmedical devices that desires to market a MSC Exosome product fromEvoBio as a private label on an exclusive basis. The Company believesthe new relationship will generate at least $2 million in newrevenue.
Jim Morrison,former L'Oréal President and Emergent’s full time CEO stated,“Our expansion of Evolutionary Biologics has continued beyond ouroriginal strategy. As I mentioned earlier this year, we have created arelationship with a state-of-the-art laboratory which has enabled usto not only manufacture the highest quality products for ourselves,but to manufacture world class products for strategic partners thatcan be marketed as “private label.” This new initiative comes aswe continue to prepare the company for major growth andexpansion.”
OnTuesday of this week, Emergent announced the engagement of BF Borgers CPA PC , a full-serviceaudit, tax, accounting, and advisory firm, as its Public CompanyAccounting Oversight Board (“PCAOB”) qualified auditor to auditthe Company’s PharmaZu subsidiary’s financial statement for thetwo-year period ending December 31, 2022 according to GenerallyAccepted Accounting Principles (“GAAP”). GAAP is the accountingstandard adopted by the Securities and Exchange Commission (“SEC”)and is the default accounting standard used by companies based in theUnited States. For further information, please see PressRelease dated May 9 th , 2023.
On Thursday of lastweek, Emergent announced the engagement of Boustead SecuritiesLLC. to act as exclusive financial advisor with respect to aplanned corporate financing transaction including the privateplacement of securities (“pre-IPO Financing”) and a planned $10million initial public offering of Emergent;s subsidiary, PharmaZu and its common stock(“IPO”) that will apply for listing on NASDAQ with NO DILUTION tothe Emergent Shareholders. PharmaZu is a pure play, e-commerceproducts and service provider focused on the Pet Community, PetPharmacy and Pet Wellness, using Influencers and their content,including pet pharmacy, vet telehealth and pet wellness businesses.Upon the effectiveness of the IPO and listing on NASDAQ, PharmaZuplans to acquire a 48-state authorized compounding pharmacy located inWest Palm Beach, FL, doing approximately $10M a year in revenue, whichwill serve as the backbone and fulfilment center for PharmaZu,creating a national platform throughout the United States. The raiseof capital will be used for expanding PharmaZu’s business, productofferings, as well as for acquisitions. Subsequently, Emergent plansto distribute the shares of PharmaZu as a dividend to itsshareholders, pro rata at NO COST to the Emergent Shareholders. Forfurther information, please see PressRelease dated May 4 th , 2023.
ABOUT EMERGENT HEALTHCORPORATION
Emergent curates, develops and sells products in theRegenerative Health Space. Its products comprise of ingestibles aswell as topicals for the whole family. The company distributes itsproducts online and through Content Based Shopping using Influencersto position products in their produced content throughout the UnitedStates and Internationally. Its subsidiaries; PharmaZu , is a pureplay, e-commerce products and service provider focused on the PetCommunity, Pet Pharmacy and Pet Wellness using Influencers and theircontent, including the pet pharmacy, vet telehealth and pet wellnessbusinesses; Regen BioWellness, is a distributor of various products inthe plant-based and regenerative medical fields. Evolutionary Biologics ,is a new kind of biologics company founded for a clear purpose: bringcutting edge regenerative products to the medical community. Emergentdoes not claim any of its products are approved by the FDA todiagnose, treat, cure or prevent any disease. For more information,please visit Emergent's Website and Social Mediaon .
Before usingany products, you should always consult with your Veterinarian and/orFamily Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-lookingstatements that can be identified by terminology such as“believes,” “expects,” “potential,” “plans,”“suggests,” “may,” “should,” “could,” “intends,”or similar expressions. Many forward-looking statements involve knownand unknown risks, uncertainties and other factors that may causeactual results to be materially different from any future resultsimplied by such statements. These factors include, but are not limitedto, our ability to continue to enhance our products and systems toaddress industry changes, our ability to expand our customer base andretain existing customers, our ability to effectively compete in ourmarket segment, the lack of public information on our company, ourability to raise sufficient capital to fund our business, operations,our ability to continue as a going concern, and a limited publicmarket for our common stock, among other risks. Many factors aredifficult to predict accurately and are generally beyond thecompany's control. Forward-looking statements speak only as to thedate they are made, and we do not undertake to update forward-lookingstatements to reflect circumstances or events that occur after thedate the forward-looking statements are made.
FOR MORE INFORMATION,PLEASE CONTACT:
Jim Morrison, CEO
Emergent HealthCorporation Website
info@emergenthealthcompany.com
ContactDetails
Emergent Health Corp.
info@emergenthealthcompany.com
CompanyWebsite
https://emergenthealthcompany.com/
Copyright (c) 2023 TheNewswire - All rights reserved.